"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at ofatumumab for mantle cell lymphoma
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at ofatumumab for mantle cell lymphoma that had come back after treatment.
Mantle cell lymphoma is a rare type of non Hodgkin lymphoma (NHL). Doctors often treat mantle cell lymphoma with chemotherapy, radiotherapy and biological therapy. But it can be difficult to treat, or can come back after treatment.
Ofatumumab has been used to treat other types of cancer, and doctors hoped it would be useful for treating mantle cell lymphoma.
The aim of this trial was to see how well ofatumumab works for mantle cell lymphoma.
Summary of results
The trial team found that ofatumumab was not likely to be a useful treatment for mantle cell lymphoma.
To begin with, this trial recruited 12 people with mantle cell lymphoma that had come back after treatment. They all had ofatumumab through a drip into a vein, once a week for up to 5 weeks.
When the research team looked at how well the treatment had worked, they found that the lymphoma had
- Got smaller in 1 person
- Stayed the same in 6 people
- Continued to grow in 5 people
The research team had hoped to recruit 34 people for this trial. But when they looked at the results of these first 12 people, they decided not to carry on recruiting.
The most common side effect was extreme tiredness (fatigue) for a couple of days after each dose of treatment. This affected 9 out of the 12 people (75%) in the trial.
The research team concluded that the dose of ofatumumab they used in this trial was not a useful treatment for mantle cell lymphoma.
We have based this summary on information from the team who ran the trial. The information they sent us has been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.
How to join a clinical trial
Prof Simon Rule
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University Hospitals Plymouth NHS Trust
Plymouth Lymphoma Trials Unit
This is Cancer Research UK trial number CRUKE/10/054.